Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIC-19: Convalescent Plasma for Vulnerable COVID-19 Patients
NCT05271929Phase 3Terminated
- Sponsor
- DRK-Blutspendedienst Baden-Württemberg-Hessen
- Start
- Apr 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of Care with Standard of Care + Convalescent Plasma (2 arms). Primary endpoint: Proportion of participants with hospitalisation with progressive COVID-19 symptoms or death at 4 weeks. Started Apr 2022; status: terminated.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05271929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271929.